REG - Argent Biopharma Ltd - Result of AGM

Argent BioPharmaAnnouncement

28/11/2024 09:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241128:nRSb0229Oa&default-theme=true

RNS Number : 0229O  Argent Biopharma Limited  28 November 2024

 

28 November 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Results of Annual General Meeting

 

Argent BioPharma is pleased to announce the voting results from the Company's
Annual General Meeting of Shareholders held today, Thursday, 28 November 2024.

The Company confirms that all motions put to the meeting were voted by poll,
with all resolutions carried.

 

Details of the results can be found in the following URL:

 

https://api.investi.com.au/api/announcements/rgt/568e91c2-8ba.pdf
(https://api.investi.com.au/api/announcements/rgt/568e91c2-8ba.pdf)

 

-Ends-

 

Authorised for release by the Company Secretary, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.co (mailto:info@argentbiopharma.co) m   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an
innovative multidisciplinary drug development Company within the
biopharmaceutical sector.  The Company focuses on multidisciplinary methods
with Nanotechnology, developing multi-target therapies for comprehensive
disease management, especially concerning the Central nervous system (CNS) and
Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFEMSUAELSESF